Caution: DXd ADC + agents with pneumonitis risk
Enhertu and its DXd cousins can inflame the lungs; combining them with immunotherapy, radiation, or mTOR inhibitors stacks that risk.
ILD ~10-15% with T-DXd; checkpoint inhibitors add 3-5%. Combination trials (DESTINY-Breast07/08, TROPION-Breast05) use careful monitoring. Thoracic radiation timing matters.
Pages like this
not linked directly; found by shared links- IdeaTest flat versus weight-based dosing of antibodies, and use dose banding to cut waste
Shares Interstitial lung disease (ILD) / pneumonitis, Trastuzumab deruxtecan, Pembrolizumab.
- TrialTROPION-Breast05
Shares Datopotamab deruxtecan, Durvalumab, Pembrolizumab.
- PersonNoboru Yamamoto
- TrialTROPION-Breast03
Shares Datopotamab deruxtecan, Durvalumab, Pembrolizumab.
- TrialDESTINY-Gastric04
Shares Interstitial lung disease (ILD) / pneumonitis, Trastuzumab deruxtecan.
- TermDXd
Shares Interstitial lung disease (ILD) / pneumonitis, Datopotamab deruxtecan, Trastuzumab deruxtecan.
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
- IdeaDose and schedule optimisation trials specific to antibody-drug conjugates
Shares Interstitial lung disease (ILD) / pneumonitis, Trastuzumab deruxtecan.